Palisade Bio (PALI) Competitors $1.60 -0.10 (-5.88%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.65 +0.05 (+3.12%) As of 10/3/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PALI vs. CLSD, NNVC, AYTU, QTTB, ALVR, ASBP, PMN, FBLG, RVPH, and TAOXShould you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Clearside Biomedical (CLSD), NanoViricides (NNVC), Aytu BioPharma (AYTU), Q32 Bio (QTTB), AlloVir (ALVR), Aspire Biopharma (ASBP), Promis Neurosciences (PMN), FibroBiologics (FBLG), Reviva Pharmaceuticals (RVPH), and Synaptogenix (TAOX). These companies are all part of the "pharmaceutical products" industry. Palisade Bio vs. Its Competitors Clearside Biomedical NanoViricides Aytu BioPharma Q32 Bio AlloVir Aspire Biopharma Promis Neurosciences FibroBiologics Reviva Pharmaceuticals Synaptogenix Palisade Bio (NASDAQ:PALI) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations. Do analysts rate PALI or CLSD? Palisade Bio presently has a consensus price target of $12.00, suggesting a potential upside of 650.00%. Clearside Biomedical has a consensus price target of $63.00, suggesting a potential upside of 1,341.65%. Given Clearside Biomedical's higher probable upside, analysts clearly believe Clearside Biomedical is more favorable than Palisade Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Palisade Bio 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Clearside Biomedical 0 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.17 Does the media prefer PALI or CLSD? In the previous week, Palisade Bio had 5 more articles in the media than Clearside Biomedical. MarketBeat recorded 8 mentions for Palisade Bio and 3 mentions for Clearside Biomedical. Palisade Bio's average media sentiment score of 0.62 beat Clearside Biomedical's score of 0.52 indicating that Palisade Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palisade Bio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Clearside Biomedical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in PALI or CLSD? 11.8% of Palisade Bio shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 0.7% of Palisade Bio shares are held by insiders. Comparatively, 6.7% of Clearside Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better earnings and valuation, PALI or CLSD? Palisade Bio has higher earnings, but lower revenue than Clearside Biomedical. Clearside Biomedical is trading at a lower price-to-earnings ratio than Palisade Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPalisade Bio$250K58.37-$14.44M-$4.06-0.39Clearside Biomedical$1.66M13.79-$34.35M-$5.55-0.79 Which has more risk and volatility, PALI or CLSD? Palisade Bio has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.05, indicating that its share price is 105% more volatile than the S&P 500. Is PALI or CLSD more profitable? Palisade Bio has a net margin of 0.00% compared to Clearside Biomedical's net margin of -665.19%. Clearside Biomedical's return on equity of 0.00% beat Palisade Bio's return on equity.Company Net Margins Return on Equity Return on Assets Palisade BioN/A -214.94% -135.09% Clearside Biomedical -665.19%N/A -124.15% SummaryPalisade Bio beats Clearside Biomedical on 9 of the 16 factors compared between the two stocks. Get Palisade Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PALI vs. The Competition Export to ExcelMetricPalisade BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.59M$3.35B$6.12B$10.56BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-0.3922.2886.9626.71Price / Sales58.37416.93588.14233.84Price / CashN/A46.3226.3031.09Price / Book0.599.9012.536.57Net Income-$14.44M-$52.45M$3.30B$276.78M7 Day Performance73.59%5.05%3.53%1.98%1 Month Performance155.39%10.61%6.77%9.13%1 Year Performance-53.35%25.03%70.60%31.60% Palisade Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PALIPalisade Bio2.2835 of 5 stars$1.60-5.9%$12.00+650.0%-53.4%$14.59M$250K-0.3910Short Interest ↑Gap UpCLSDClearside Biomedical2.9861 of 5 stars$4.41+0.3%$63.00+1,330.2%-79.9%$23.19M$1.66M-0.8030NNVCNanoViricides0.2901 of 5 stars$1.44-0.7%N/A-6.1%$23.06MN/A-1.9920AYTUAytu BioPharma3.6033 of 5 stars$2.55+2.5%$10.00+291.8%-19.1%$22.94M$81M-3.55160QTTBQ32 Bio2.9238 of 5 stars$1.89+1.1%$12.17+543.7%-95.4%$22.57M$1.16M-0.4339Analyst UpgradeALVRAlloVirN/A$4.40-3.1%N/A-63.2%$22.19MN/A-0.22110High Trading VolumeASBPAspire BiopharmaN/A$0.45+6.0%N/AN/A$22.06MN/A0.00N/AGap DownPMNPromis Neurosciences2.6274 of 5 stars$0.42-1.2%$4.33+922.0%-54.3%$21.97MN/A-2.025Negative NewsFBLGFibroBiologics1.9592 of 5 stars$0.52-1.0%$12.50+2,290.1%-80.7%$21.91MN/A-1.4510RVPHReviva Pharmaceuticals3.6424 of 5 stars$0.31+1.5%$5.33+1,609.4%-56.4%$21.63MN/A-0.485Analyst UpgradeGap UpHigh Trading VolumeTAOXSynaptogenix0.0575 of 5 stars$5.93+1.2%N/AN/A$20.70MN/A-0.294 Related Companies and Tools Related Companies CLSD Alternatives NNVC Alternatives AYTU Alternatives QTTB Alternatives ALVR Alternatives ASBP Alternatives PMN Alternatives FBLG Alternatives RVPH Alternatives TAOX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PALI) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersThis soon could be the most precious company in AmericaCurrently, a brand-new, all-American factory outside San Antonio is becoming the most significant site in the ...True Market Insiders | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredChina’s New Gold Play Could Make your Income SoarChina's New Gold Move Could Pay You up to $1,152/month. China just announced plans to store other nations' ...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palisade Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palisade Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
